What is the recommended duration of intravenous antibiotic therapy for bacteremia, including variations for different organisms such as Gram‑negative bacilli, Staphylococcus aureus, and Streptococcus pneumoniae?

Antibiotic Duration for Bacteremia

For uncomplicated Gram-negative bacteremia (primarily Enterobacterales), treat for 7 days once the patient is hemodynamically stable and afebrile for 48 hours; for Staphylococcus aureus bacteremia, treat for 4-6 weeks if high-risk features are present, or 14 days for uncomplicated cases; for Streptococcus pneumoniae bacteremia secondary to pneumonia, 5-10 days is appropriate once clinical stability is achieved.

Gram-Negative Bacteremia (Enterobacterales)

The evidence for short-course therapy in Gram-negative bacteremia is robust and practice-changing:

• 7 days is now standard for uncomplicated Gram-negative bacteremia once patients achieve clinical stability (afebrile and hemodynamically stable for ≥48 hours) 1
• A 2025 meta-analysis of 4 RCTs (4,790 patients) found no difference in 90-day mortality (13.3% vs 14.3%), recurrence (2.7% vs 2.3%), or adverse events between 7-day and 14-day courses 2
• An individual patient data meta-analysis of 3 RCTs (1,186 patients) confirmed these findings across all subgroups: age, gender, hemodynamic status, immune status, and infection source 3

Key prerequisites for 7-day therapy:

• Hemodynamically stable for ≥48 hours
• Afebrile for ≥48 hours
• Adequate source control achieved
• No evidence of metastatic infection or endocarditis

Common pitfall: Extending therapy beyond 7 days in stable patients with controlled source—this is now considered inappropriate stewardship practice 4. The urinary tract is the most common source (68% of cases), and these patients particularly benefit from shorter courses 1.

Staphylococcus aureus Bacteremia

S. aureus bacteremia requires substantially longer treatment due to high risk of metastatic complications:

• 4-6 weeks for complicated/high-risk cases 5
• 14 days for truly uncomplicated cases (though these are rare) 6

High-risk features requiring 4-6 weeks:

• Persistent bacteremia (positive cultures after 5 days of appropriate therapy)
• No identifiable removable focus
• Prosthetic material present
• Vertebral involvement or other deep-seated infection
• Immunosuppression
• Valvular dysfunction 6

Critical management points:

• Use cefazolin or anti-staphylococcal penicillin for MSSA (superior to vancomycin)
• Use vancomycin or daptomycin for MRSA with appropriate dosing 5
• Early source control is mandatory
• Both TTE and TEE should be performed to exclude endocarditis 5

Common pitfall: Treating uncomplicated S. aureus bacteremia for only 7 days—this organism requires longer therapy than Gram-negatives due to its propensity for metastatic seeding. Even "uncomplicated" cases warrant 14 days minimum 6.

Streptococcus pneumoniae Bacteremia

For S. pneumoniae bacteremia secondary to community-acquired pneumonia:

• 5-10 days is appropriate once clinical stability is achieved by day 10 7
• A 2024 retrospective study (162 patients, 90% with pneumonia as source) found no difference in clinical failure rates between short (5-10 days, median 7) and long (11-16 days, median 14) courses 7

Requirements for short-course therapy:

• Clinical stability achieved by day 10
• No invasive infection (meningitis, endocarditis)
• Monomicrobial infection
• Active antibiotics initiated within 48 hours of positive culture 7

Algorithmic Approach to Duration

Step 1: Identify the organism

• Gram-negative (Enterobacterales) → proceed to Step 2
• S. aureus → assess for high-risk features → 4-6 weeks if present, 14 days minimum if absent
• S. pneumoniae with pneumonia source → 5-10 days if stable by day 10

Step 2: For Gram-negatives, assess clinical stability at 48 hours

• Afebrile AND hemodynamically stable → proceed to Step 3
• Not stable → continue therapy, reassess daily

Step 3: Confirm source control and exclude complications

• Source controlled (catheter removed, abscess drained, etc.) → 7 days total
• Uncontrolled source or metastatic infection → individualized longer course

Step 4: Exclude high-risk scenarios

• No endocarditis, no undrainable abscess, no immunosuppression requiring longer therapy → 7 days
• High-risk features present → extend duration based on specific complication

Safety and Stewardship Considerations

The shift to shorter durations has demonstrated:

• No increase in mortality, relapse, or complications 2, 3, 1
• Reduced antibiotic exposure and associated adverse events
• Shorter hospital stays in some studies
• Lower risk of C. difficile infection and antibiotic resistance 2

The most important caveat: These shorter durations apply only to patients who achieve clinical stability and have adequate source control. Persistent fever, hemodynamic instability, or uncontrolled infection source mandate longer therapy regardless of organism.